The Hepatitis C Drug Market is estimated at US$15.1 billion in 2026 and is projected to grow at a CAGR of 19.5% to reach US$62.8 billion by 2034.
Suppliers also navigate case finding gaps, affordability in some regions, reinfection risk, adherence barriers, and uneven screening coverage. Competition spans innovator pharma companies, generic suppliers, public health procurement channels, and access focused partnerships, and differentiation depends on performance, service quality, compliance readiness, and customer trust.
This product will be delivered within 1-3 business days.
Market Overview
Hepatitis C Drug Market covers drug therapies used to treat chronic and acute hepatitis C infection across specialist and public health settings. The value chain includes drug developers, generic manufacturers, public procurement agencies, hospitals, clinics, and diagnostic partners, supporting use across viral eradication programs, hospital treatment, public health screening pathways, and liver disease management.Suppliers also navigate case finding gaps, affordability in some regions, reinfection risk, adherence barriers, and uneven screening coverage. Competition spans innovator pharma companies, generic suppliers, public health procurement channels, and access focused partnerships, and differentiation depends on performance, service quality, compliance readiness, and customer trust.
Key Companies Analysed
- Gilead Sciences
- AbbVie
- Bristol Myers Squibb
- Merck & Co.
- Roche
- Johnson & Johnson
- Aurobindo Pharma
- Cipla
- Dr. Reddy's Laboratories
- Sun Pharma
- Mylan
- Zydus Lifesciences
- Hetero
- Natco Pharma
- Apotex
- Lupin
- Torrent Pharmaceuticals
- Teva
- Strides Pharma
- Beximco Pharma
Geographic Coverage
- North America - Market data and outlook to 2034
- United States
- Canada
- Mexico
- Europe - Market data and outlook to 2034
- Germany
- United Kingdom
- France
- Italy
- Spain
- Netherlands
- Switzerland
- Poland
- Sweden
- Russia
- Asia-Pacific - Market data and outlook to 2034
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Malaysia
- Vietnam
- Middle East and Africa - Market data and outlook to 2034
- Saudi Arabia
- South Africa
- Iran
- UAE
- Egypt
- South and Central America - Market data and outlook to 2034
- Brazil
- Argentina
- Chile
- Peru
Report Delivery and Support
- Updated PDF report and an MS Excel workbook containing market tables and figures.
- 7-day post-sale analyst support for clarifications and in-scope supplementary data.
- Complimentary report update covering the latest available data and relevant market developments.
This product will be delivered within 1-3 business days.
Table of Contents
1. Contents and Report Guide
2. Global Hepatitis C Drug Market Overview
3. Hepatitis C Drug Market Dynamics
4. Hepatitis C Drug Market Strategic Analysis
5. Global Hepatitis C Drug Market Size, Share and Forecast, 2025-2034
6. North America Hepatitis C Drug Market Outlook to 2034
7. Europe Hepatitis C Drug Market Outlook to 2034
8. Asia-Pacific Hepatitis C Drug Market Outlook to 2034
9. Middle East and Africa Hepatitis C Drug Market Outlook to 2034
10. South and Central America Hepatitis C Drug Market Outlook to 2034
11. Hepatitis C Drug Market Competitive Landscape
12. Appendix
Companies Mentioned
- Gilead Sciences
- AbbVie
- Bristol Myers Squibb
- Merck & Co.
- Roche
- Johnson & Johnson
- Aurobindo Pharma
- Cipla
- Dr. Reddy's Laboratories
- Sun Pharma
- Mylan
- Zydus Lifesciences
- Hetero
- Natco Pharma
- Apotex
- Lupin
- Torrent Pharmaceuticals
- Teva
- Strides Pharma
- Beximco Pharma
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | October 2026 |
| Forecast Period | 2026 - 2034 |
| Estimated Market Value ( USD | $ 15.1 Billion |
| Forecasted Market Value ( USD | $ 62.8 Billion |
| Compound Annual Growth Rate | 19.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
